Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Getting Somewhat Favorable Media Coverage, Report Finds

News articles about Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) have trended somewhat positive on Saturday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.4389480832974 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment’s rankings:

A number of equities analysts have weighed in on the stock. BidaskClub upgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research lowered shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Roth Capital set a $14.00 price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $21.50.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) opened at $10.51 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12-month low of $7.52 and a 12-month high of $12.30. The firm has a market cap of $392.02, a P/E ratio of 5.53 and a beta of 1.34.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.13. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The firm had revenue of $39.68 million during the quarter, compared to analyst estimates of $38.22 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s revenue for the quarter was up 23.7% on a year-over-year basis. sell-side analysts anticipate that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.32 EPS for the current year.

In related news, Director Craig R. Stapleton bought 140,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average price of $8.67 per share, for a total transaction of $1,213,800.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Craig R. Stapleton sold 254,265 shares of the company’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $9.35, for a total transaction of $2,377,377.75. Following the transaction, the director now owns 253,413 shares of the company’s stock, valued at approximately $2,369,411.55. The disclosure for this sale can be found here. 5.07% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece was first published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thestockobserver.com/2018/01/13/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-getting-somewhat-favorable-media-coverage-report-finds.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply